A recombinant human monoclonal anti-R7V antibody as a potential therapy for HIV infected patients in failure of HAART.
The construction of a recombinant antibody directed against the cellular epitope R7V acquired by HIV during the viral budding has been realized. The c-DNAs encoding the variable regions of the anti-R7V antibody have been cloned from B lymphocytes of a non-progressor patient. Two transfer vectors containing complete coding sequences for heavy and light chains of this antibody were constructed and a recombinant baculovirus was generated by a double recombination between baculovirus DNA and the two transfer vectors. Insect cells infected with this baculovirus produced a complete human anti-R7V immunoglobulin. This recombinant antibody, specific to the R7V peptide, recognizes and neutralizes all clades of HIV1 including resistant viruses, opening new perspectives in anti-HIV therapy.
Haslin
Camille
C
URRMA R&D, Aubagne Cedex, France. hasliln@urrma.fr
Lévêque
Marylène
M
Ozil
Annick
A
Cérutti
Pierre
P
Chardès
Thierry
T
Chermann
Jean-Claude
JC
Duonor-Cérutti
Martine
M
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D016367:Baculoviridae / Q000235:genetics; D001483:Base Sequence; D002460:Cell Line; D015483:HIV Antibodies / Q000627:therapeutic use*; D015658:HIV Infections / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000627:therapeutic use; D018411:Spodoptera; D017211:Treatment Failure; D001613:beta 2-Microglobulin / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin